The inflammatory tumor microenvironment and its impact on cancer development.

The role of the immune system during cancer development is complex involving extensive reciprocal interactions between genetically altered cells, adaptive and innate immune cells, their soluble mediators and structural components present in the neoplastic microenvironment. Each stage of cancer development is regulated uniquely by the immune system; whereas full activation of adaptive immune cells at the tumor stage may result in eradication of malignant cells, chronic activation of innate immune cells at sites of premalignant growth may actually enhance tumor development. In addition, the balance between desirable antitumor immune responses and undesirable pro-tumor chronic inflammatory responses largely depends on the context in which a malignancy is developing. The following chapter focuses on the inflammatory components and processes engaged during cancer development and the impact of the inflammatory microenvironment.

[1]  D. McDonald,et al.  Significance of blood vessel leakiness in cancer. , 2002, Cancer research.

[2]  A. Luster The role of chemokines in linking innate and adaptive immunity. , 2002, Current opinion in immunology.

[3]  G. Dranoff Coordinated tumor immunity , 2003 .

[4]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[5]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[6]  F. Balkwill Tumor necrosis factor or tumor promoting factor? , 2002, Cytokine & growth factor reviews.

[7]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[8]  F. Belardelli,et al.  Cytokines as a link between innate and adaptive antitumor immunity. , 2002, Trends in immunology.

[9]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[10]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[11]  S. Cingarlini,et al.  Derangement of immune responses by myeloid suppressor cells , 2004, Cancer Immunology, Immunotherapy.

[12]  S. Aulmann,et al.  Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. , 2005, The American journal of pathology.

[13]  T. Kupper,et al.  Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. , 2000, The Journal of investigative dermatology.

[14]  M. Herlyn,et al.  Low-Level Monocyte Chemoattractant Protein-1 Stimulation of Monocytes Leads to Tumor Formation in Nontumorigenic Melanoma Cells1 , 2001, The Journal of Immunology.

[15]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[16]  H. Adami,et al.  Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.

[17]  Hans Clevers,et al.  At the Crossroads of Inflammation and Cancer , 2004, Cell.

[18]  M. Thun,et al.  Inflammation and cancer: an epidemiological perspective. , 2004, Novartis Foundation symposium.

[19]  Y. Matsuzaki,et al.  Effect of mast cells on tumor angiogenesis in lung cancer. , 2000, The Annals of thoracic surgery.

[20]  L. Coussens,et al.  Extrinsic regulators of epithelial tumor progression: metalloproteinases. , 2000, Current opinion in genetics & development.

[21]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[22]  T. Koike,et al.  The polymorphism interleukin 8 −251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population , 2005, Gut.

[23]  H. Macdonald,et al.  The Early IL-4 Response to Leishmania major and the Resulting Th2 Cell Maturation Steering Progressive Disease in BALB/c Mice Are Subject to the Control of Regulatory CD4+CD25+ T Cells1 , 2002, The Journal of Immunology.

[24]  L. Coussens,et al.  Early neoplastic progression is complement independent. , 2004, Neoplasia.

[25]  G. Friedman,et al.  Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.

[26]  N. Funel,et al.  Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma , 2004, Journal of Clinical Pathology.

[27]  T. Schumacher,et al.  CD8+ T Cell Tolerance and Cancer Immunotherapy , 2003, Journal of immunotherapy.

[28]  D. Hanahan,et al.  Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. , 1996, The American journal of pathology.

[29]  J. Ferlay,et al.  Cancer and infection: estimates of the attributable fraction in 1990. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  P. Maisonneuve,et al.  Chronic Pancreatitis and Pancreatic Cancer , 2002, Digestive Diseases.

[31]  S. Tonegawa Somatic generation of antibody diversity , 1983, Nature.

[32]  S. Stacker,et al.  Focus on lymphangiogenesis in tumor metastasis. , 2005, Cancer cell.

[33]  L. Coussens,et al.  Cancer: An inflammatory link , 2004, Nature.

[34]  I. Fidler,et al.  Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. , 2002, Journal of the National Cancer Institute.

[35]  S. Okushiba,et al.  Long-term survival after radical resection of advanced pancreatic cancer , 2003, International journal of gastrointestinal cancer.

[36]  I. Wistuba,et al.  Gallbladder cancer: lessons from a rare tumour , 2004, Nature Reviews Cancer.

[37]  Nigel J. Saunders,et al.  CD4+CD25+ TR Cells Suppress Innate Immune Pathology Through Cytokine-dependent Mechanisms , 2003, The Journal of experimental medicine.

[38]  J. Pollard,et al.  Macrophages: modulators of breast cancer progression. , 2004, Novartis Foundation symposium.

[39]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[40]  J. Sprent,et al.  T cell memory. , 2003, Annual review of immunology.

[41]  H. Ohtani,et al.  Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis , 2004, British Journal of Cancer.

[42]  B. Gold,et al.  The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. , 2000, Annual review of microbiology.

[43]  Shu-Hsia Chen,et al.  Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.

[44]  S. Takeno,et al.  Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. , 2003, Oncology reports.

[45]  F. Balkwill Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[46]  P. Ernst,et al.  Review article: the role of inflammation in the pathogenesis of gastric cancer , 1999, Alimentary pharmacology & therapeutics.

[47]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[48]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[49]  S. Sakaguchi Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[50]  P Boffetta,et al.  A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma , 1998, International journal of cancer.

[51]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[52]  H. Choy,et al.  Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? , 2003, Journal of the National Cancer Institute.

[53]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[54]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[55]  D. Hanahan,et al.  Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells , 2003, The Journal of experimental medicine.

[56]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[57]  T. Oshikiri,et al.  Clinical significance of immune cell infiltration within gallbladder cancer , 2003, British Journal of Cancer.

[58]  Koichi Yamazaki,et al.  CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non‐small cell lung cancers , 2003, Cancer science.

[59]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[60]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[61]  R. DuBois,et al.  Cyclooxygenase‐2 and Gastrointestinal Cancer , 2004, Cancer journal.

[62]  Olivier De Wever,et al.  Role of tissue stroma in cancer cell invasion , 2003, The Journal of pathology.

[63]  H. Kojima,et al.  Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. , 2000, The European respiratory journal.

[64]  L. Norton,et al.  Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.

[65]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[66]  E. Heathcote,et al.  Prevention of hepatitis C virus-related hepatocellular carcinoma. , 2004, Gastroenterology.

[67]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[68]  Blossom Damania,et al.  Infectious agents and cancer: criteria for a causal relation. , 2004, Seminars in cancer biology.

[69]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[70]  B. Evers,et al.  Inflammation and the development of pancreatic cancer. , 2002, Surgical oncology.

[71]  J. Masferrer,et al.  Celecoxib: a specific COX-2 inhibitor with anticancer properties. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[72]  N. Restifo,et al.  Creating therapeutic cancer vaccines: notes from the battlefield. , 2001, Trends in immunology.

[73]  P. Allavena,et al.  Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. , 2004, European journal of cancer.

[74]  J. Okamura,et al.  Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis , 1999, Gastric Cancer.

[75]  S. Piantadosi,et al.  Primary chemoprevention of familial adenomatous polyposis with sulindac , 2002 .

[76]  T. Tlsty,et al.  Stromal cells can contribute oncogenic signals. , 2001, Seminars in cancer biology.

[77]  H. Maeda,et al.  Nitric oxide and oxygen radicals in infection, inflammation, and cancer. , 1998, Biochemistry. Biokhimiia.

[78]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[79]  G. Gasparini,et al.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? , 2003, The Lancet. Oncology.

[80]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[81]  H. Nagai,et al.  Helicobacter pylori infection induces gastric cancer in mongolian gerbils. , 1998, Gastroenterology.

[82]  I. Takanami,et al.  Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma , 2000, Cancer.

[83]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[84]  S. Jimi,et al.  Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. , 2000, Human pathology.

[85]  R. DuBois,et al.  COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.

[86]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[87]  L. Benítez-Bribiesca,et al.  The Role of Mast Cell Tryptase in Neoangiogenesis of Premalignant and Malignant Lesions of the Uterine Cervix , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[88]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[89]  J. Nyhus,et al.  Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. , 2002, Cancer research.

[90]  D. Forman,et al.  An international association between Helicobacter pylori infection and gastric cancer , 1993 .

[91]  T. Fujioka,et al.  Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. , 1998, Cancer research.

[92]  K. Seibert,et al.  The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.

[93]  L. A. Richards,et al.  Increased mast cell density in invasive melanoma , 1998, Journal of cutaneous pathology.

[94]  D. Gabrilovich,et al.  Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells1 , 2001, The Journal of Immunology.

[95]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[96]  D. Gabrilovich,et al.  Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.

[97]  H. Jick,et al.  Association Between Acetaminophen or Nonsteroidal Antiinflammatory Drugs and Risk of Developing Ovarian, Breast, or Colon Cancer , 2002, Pharmacotherapy.

[98]  Christian Bréchot,et al.  Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. , 2004, Gastroenterology.

[99]  T. Oshikiri,et al.  Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response , 2003, Journal of surgical oncology.

[100]  Yasmine Belkaid,et al.  Natural regulatory T cells in infectious disease , 2005, Nature Immunology.

[101]  L. Coussens,et al.  Inflammation and matrix metalloproteinases: implications for cancer development , 2004 .

[102]  S. Prescott,et al.  Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer , 2002, Journal of cellular physiology.

[103]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[104]  F. Chisari,et al.  Immune Pathogenesis of Hepatocellular Carcinoma , 1998, The Journal of experimental medicine.

[105]  S. Weitzman,et al.  Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. , 1990, Blood.

[106]  D. Whitcomb Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[107]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[108]  A. De Luca,et al.  Helicobacter pylori and gastric diseases: a dangerous association. , 2004, Cancer letters.

[109]  Charles A. Janeway,et al.  INAUGURAL ARTICLE by a Recently Elected Academy Member:How the immune system works to protect the host from infection: A personal view , 2001 .

[110]  C. López-Otín,et al.  Protease degradomics: A new challenge for proteomics , 2002, Nature Reviews Molecular Cell Biology.

[111]  A. Sabichi,et al.  Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. , 2005, Cancer research.

[112]  R. DuBois,et al.  Cyclooxygenase-2: a therapeutic target. , 2002, Annual review of medicine.

[113]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[114]  L. Hansson,et al.  Aspirin and risk for gastric cancer: a population-based case–control study in Sweden , 2001, British Journal of Cancer.

[115]  J. Renauld New insights into the role of cytokines in asthma , 2001, Journal of clinical pathology.

[116]  D. Hanahan,et al.  Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice , 1994, Journal of virology.

[117]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[118]  V. Bronte,et al.  L-arginine metabolism in myeloid cells controls T-lymphocyte functions. , 2003, Trends in immunology.

[119]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[120]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[121]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[122]  H. Ohshima Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. , 2003, Toxicology letters.

[123]  J A Hanley,et al.  Nested caseÐcontrol study of the effects of non- steroidal anti-inflammatory drugs on breast cancer risk and stage , 2000 .

[124]  L. Matrisian,et al.  Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.

[125]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[126]  Toru Watanabe,et al.  Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. , 2002, Anticancer research.

[127]  M. Cotterchio,et al.  Nonsteroidal anti-inflammatory drug use and breast cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[128]  M. Bevan,et al.  Selecting and maintaining a diverse T-cell repertoire , 1999, Nature.

[129]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[130]  M. McHeyzer-Williams,et al.  B cells as effectors. , 2003, Current opinion in immunology.

[131]  W. Schürch,et al.  Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[132]  F. Marks,et al.  Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[133]  M. Fernández-arquero,et al.  Interleukin-10 polymorphisms in Spanish type 1 diabetes patients , 2004, Genes and Immunity.

[134]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[135]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[136]  Xianglin Shi,et al.  Diseases caused by silica: mechanisms of injury and disease development. , 2002, International immunopharmacology.

[137]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[138]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[139]  M. Carroll,et al.  The complement system in regulation of adaptive immunity , 2004, Nature Immunology.

[140]  L. G. García Rodríguez,et al.  Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs , 2001, Epidemiology.

[141]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[142]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[143]  J. Demengeot,et al.  CD25+CD4+ regulatory T cells suppress CD4+ T cell‐mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice , 2002 .

[144]  G. Forni,et al.  Immunological inhibition of carcinogenesis , 2004, Cancer Immunology, Immunotherapy.